Back to search

Antiretroviral pharmacokinetic profile: A review of sex differences

Data up to Jan 2025

Published2007
Citations100
References32

Total Citations Per Year

Abstract

References (32)

Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

1999 • 850 citations

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

2001 • 828 citations

Sex Differences in Nevirapine Rash

2001 • 216 citations

Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer

2002 • 211 citations

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

2001 • 209 citations

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

2001 • 172 citations

Survival differences in patients with AIDS.

1991 • 139 citations

Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America

1999 • 137 citations

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

2003 • 134 citations

Human Immunodeficiency Virus Infection in North American Women

1991 • 131 citations

Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398

2002 • 129 citations

Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

2000 • 97 citations

Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individuals

2002 • 96 citations

Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients

1999 • 90 citations

Population pharmacokinetic meta-analysis with efavirenz

2002 • 87 citations

Sex‐Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359

2004 • 82 citations

Sex differences in HAART-associated dyslipidaemia

2001 • 81 citations

Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

2000 • 81 citations

Adverse Events from Drug Therapy for Human Immunodeficiency Virus Disease

1996 • 71 citations

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

1994 • 70 citations

Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults

2004 • 60 citations

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

2003 • 59 citations

Simplifying Protease Inhibitor Therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study

2002 • 56 citations

Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus

2004 • 36 citations

Sex‐Related Differences in the Pharmacokinetics of Once‐Daily Saquinavir Soft‐Gelatin Capsules Boosted with Low‐Dose Ritonavir in Patients Infected with Human Immunodeficiency Virus Type 1

2004 • 34 citations

Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor

2001 • 26 citations

Sex differences in nevirapine disposition in HIV-infected patients

2003 • 24 citations

Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting Syndrome

2004 • 21 citations

Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals

2005 • 15 citations

Lack of sex‐related differences in saquinavir pharmacokinetics in an HIV‐seronegative cohort

2006 • 9 citations

Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor

2001 • 7 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...